Garland reported fourth-quarter adjusted gross profit of $104 million and adjusted gross margin of 52.4%, an increase of 170 basis points year-over-year. He attributed the improvement primarily to volume leverage and price, which more than offset inflation, with “slight headwinds from mix and tariffs.” For the full year, adjusted gross margin was 52.6%, up about 220 basis points from 2024 on similar drivers.CFO Jason Garland said acquisitions contributed about one percentage point to fourth-quarter reported ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker12I would now like to turn the conference over to Jacob Johnson, Vice President, Investor Relations. You may begin.Speaker5Thank you, operator, and welcome everyone to our 2025 fourth quarter report. On this call, we will cover business highlights and financial performance for the three and 12-month periods ended December 31st, 2025, and we'll provide financial guidance for the full year 2026. Joining us on the call today ar ...

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporatio ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying conditions revealed extreme volatility and market leadership. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Small Cap Strategy returned -1.89% net-of-fees, trailing the Russell 2000 Growth Index’s 1.22% return. The returns were volatile i ...

Core Viewpoint - Repligen Corporation will report its fourth quarter 2025 financial results on February 24, 2026, with a conference call scheduled for 8:30 a.m. ET to discuss the results and business updates [1]. Group 1: Financial Reporting - The financial results will cover the three- and twelve-month periods ending December 31, 2025 [1]. - A press release will be issued before the market opens on the reporting date [1]. Group 2: Conference Call Details - The conference call can be accessed by domestic callers at toll-free number (800) 715-9871 and international callers at (646) 307-1963, with no passcode required [2]. - A webcast of the conference call will be available on the Investor Relations section of the company's website, and both the call and webcast will be archived for later access [2]. Group 3: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3]. - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3]. - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3].

Financial Data and Key Metrics Changes - For the full year 2025, sales reached $24.6 billion, with core revenue increasing by 2% [9] - Adjusted operating profit margin was 28.2%, and adjusted diluted net earnings per common share were $7.80, up 4.5% year-over-year [9] - Free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [10] Business Line Data and Key Metrics Changes - Biotechnology segment core revenue increased by 6% [16] - Bioprocessing core revenue grew high single digits, with consumables and equipment both contributing to growth [16] - Life sciences segment core revenue increased by 0.5%, with consumables experiencing a decline due to lower demand [19] - Diagnostics segment core revenue increased by 2%, with clinical diagnostics growing mid-single digits [20] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [15] - High growth markets saw mid-single digit increases, with solid growth outside of China, offsetting a low single-digit decline in China [15] Company Strategy and Development Direction - The company aims for long-term value creation through a differentiated portfolio and the Danaher Business System [9] - Continued investments in innovation led to over 20 new product launches in biotechnology, enhancing customer capabilities [10] - The company anticipates high single-digit core revenue growth in bioprocessing for 2026, driven by strong underlying biologic demand [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual end market improvements continuing into 2026, particularly in bioprocessing and diagnostics [9][23] - The company expects core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [23] Other Important Information - The company has maintained a free cash flow to net income conversion ratio exceeding 100% for 34 consecutive years [10] - The FDA approved several new products, including Cepheid's Xpert GI Panel, enhancing the company's diagnostic capabilities [12] Q&A Session Summary Question: Insights on core revenue guidance - Management indicated that the 3%-6% core revenue guidance reflects expectations of continued recovery in end markets, particularly in bioprocessing and diagnostics [31][33] Question: Bioprocessing order book and growth outlook - The order book supports high single-digit growth for bioprocessing, with consumables expected to perform well [36][105] Question: Strength in SCIEX and end market recovery - SCIEX experienced mid-single-digit growth, driven by innovation and improvements in the pharma end market [42] Question: Margin expectations for 2026 - Management expects low single-digit core growth to translate into margin improvements, with benefits from cost actions contributing to earnings [44][78] Question: Biotech funding environment impact - The biotech segment is sensitive to funding improvements, which could enhance order volumes in the future [95][96]

Core Insights - Danaher Corporation is expected to report positive quarterly earnings, with significant orders from biotech companies indicating a potential turnaround after a prolonged period of underperformance [1] - The stock has shown a notable recovery, increasing 31% from its April low and 25% from its September low, driven by strong growth in the bioprocessing division [2] - Wall Street anticipates that Danaher will achieve its best growth in years in 2026, with mid-single-digit revenue growth and high single-digit earnings growth projected [2] Company Overview - Danaher Corporation specializes in instruments, consumables, software, and services for bioprocessing, life sciences research, and clinical diagnostics [2] - The company has shifted focus towards life sciences diagnostics after spinning off its water and product quality testing business, Veralto [2] Recent Performance - In late October, Danaher reported a strong quarter with a small revenue beat and 3% organic growth, alongside a significant earnings beat [2] - Despite previous frustrations with stock performance, recent results have led to a positive outlook and increased stock movement [2]

Core Insights - Repligen Corporation (NASDAQ:RGEN) is identified as a leading mid-cap growth stock, with UBS raising its price target to $200 from $190 while maintaining a Buy rating, indicating strong confidence in the company's future performance [1] - The company is positioned to benefit from a recovery in the bioprocessing sector, driven by over 20% order growth and the trend of reshoring production closer to primary markets by 2026 [1][3] Company Developments - Repligen recently launched three new high-performance chromatography resins: AVIPure HiPer AAV9, AVIPure HiPer AAV8, and HiPer QA, which enhance its protein portfolio and cater to next-gen bioprocessing needs, particularly for gene therapy applications [2] - The new resins utilize Tantti DuloCore base bead technology to improve molecule stability, accelerate product development, and enhance process economics for gene therapy developers [3] Market Position - Repligen is recognized as a core beneficiary in the biopharma sector as companies increasingly move production closer to their markets, which is expected to be a significant trend by 2026 [1][3] - The company's advancements in chromatography technology are aimed at providing faster processing times and improved performance for complex biotherapeutic workflows [3]

Company Overview - Repligen is headquartered in Waltham, Massachusetts and employs approximately 2,000 people [2][3] - The company focuses on bioprocessing and has dual manufacturing capabilities in the U.S. and Europe [3] Financial Guidance - For 2025, Repligen projects sales to reach USD 733 million at the midpoint of their guidance [3] Vision and Strategy - The company's vision is to be the global leader in bioprocessing innovation, offering a diverse portfolio of data-driven solutions across various therapeutic modalities [4] - Innovation has been a key focus for Repligen over the past decade, positioning the company in a large bioprocessing market with significant competition [5]